RNA-seq and FCM analyses independently demonstrated heterogeneous abundance of potentially tumor-specific CD8+ T cells in brain tumors, enabling the separation of the cohorts into three groups: glioma (pTRT cell-low), pTRT cell-low BrM and pTRT cell-high BrM. This evidence concerns the gene CD8A and central nervous system cancer.